| Noi Walkenstein, DO | |
|
2607 Rhawn St, Philadelphia, PA 19152-3038 | |
| (215) 333-0304 | |
| (215) 333-1402 |
| Full Name | Noi Walkenstein |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 33 Years |
| Location | 2607 Rhawn St, Philadelphia, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003852013 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | OS007932L (Pennsylvania) | Secondary |
| 207R00000X | Internal Medicine | OS007932L (Pennsylvania) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Spuc, Llc | 2466779285 | 4 |
News Archive
A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.
Cancer tissue cells are divided into two major groups: cancer cells and cancer stem cells. CSCs are related to cancer progression and dissemination, so it's necessary to eradicate CSCs in order to cure cancer.
Gilead Sciences Inc. announced Thursday that it plans to partner with Mylan Inc., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. "to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries," the Wall Street Journal reports.
The Nova Scotia government's decision to limit Pharmacare coverage of blood glucose test strips for some diabetes patients places a significant financial and health burden on these Nova Scotians and violates the fundamental principle that patients and their healthcare professionals should be able to determine how to manage treatment.
› Verified 1 days ago
| Entity Name | Primary Care Group, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245287770 PECOS PAC ID: 9830081322 Enrollment ID: O20040329000825 |
News Archive
A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.
Cancer tissue cells are divided into two major groups: cancer cells and cancer stem cells. CSCs are related to cancer progression and dissemination, so it's necessary to eradicate CSCs in order to cure cancer.
Gilead Sciences Inc. announced Thursday that it plans to partner with Mylan Inc., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. "to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries," the Wall Street Journal reports.
The Nova Scotia government's decision to limit Pharmacare coverage of blood glucose test strips for some diabetes patients places a significant financial and health burden on these Nova Scotians and violates the fundamental principle that patients and their healthcare professionals should be able to determine how to manage treatment.
› Verified 1 days ago
| Entity Name | Premier Immediate Medical Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821040890 PECOS PAC ID: 3779594221 Enrollment ID: O20060511000294 |
News Archive
A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.
Cancer tissue cells are divided into two major groups: cancer cells and cancer stem cells. CSCs are related to cancer progression and dissemination, so it's necessary to eradicate CSCs in order to cure cancer.
Gilead Sciences Inc. announced Thursday that it plans to partner with Mylan Inc., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. "to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries," the Wall Street Journal reports.
The Nova Scotia government's decision to limit Pharmacare coverage of blood glucose test strips for some diabetes patients places a significant financial and health burden on these Nova Scotians and violates the fundamental principle that patients and their healthcare professionals should be able to determine how to manage treatment.
› Verified 1 days ago
| Entity Name | Rittenhouse Internal Medicine, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568631430 PECOS PAC ID: 8820173081 Enrollment ID: O20080312000081 |
News Archive
A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.
Cancer tissue cells are divided into two major groups: cancer cells and cancer stem cells. CSCs are related to cancer progression and dissemination, so it's necessary to eradicate CSCs in order to cure cancer.
Gilead Sciences Inc. announced Thursday that it plans to partner with Mylan Inc., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. "to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries," the Wall Street Journal reports.
The Nova Scotia government's decision to limit Pharmacare coverage of blood glucose test strips for some diabetes patients places a significant financial and health burden on these Nova Scotians and violates the fundamental principle that patients and their healthcare professionals should be able to determine how to manage treatment.
› Verified 1 days ago
| Entity Name | Spuc, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518387562 PECOS PAC ID: 2466779285 Enrollment ID: O20150316001115 |
News Archive
A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.
Cancer tissue cells are divided into two major groups: cancer cells and cancer stem cells. CSCs are related to cancer progression and dissemination, so it's necessary to eradicate CSCs in order to cure cancer.
Gilead Sciences Inc. announced Thursday that it plans to partner with Mylan Inc., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. "to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries," the Wall Street Journal reports.
The Nova Scotia government's decision to limit Pharmacare coverage of blood glucose test strips for some diabetes patients places a significant financial and health burden on these Nova Scotians and violates the fundamental principle that patients and their healthcare professionals should be able to determine how to manage treatment.
› Verified 1 days ago
| Entity Name | Jefferson Acute Care Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730571324 PECOS PAC ID: 7810215613 Enrollment ID: O20150407001063 |
News Archive
A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.
Cancer tissue cells are divided into two major groups: cancer cells and cancer stem cells. CSCs are related to cancer progression and dissemination, so it's necessary to eradicate CSCs in order to cure cancer.
Gilead Sciences Inc. announced Thursday that it plans to partner with Mylan Inc., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. "to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries," the Wall Street Journal reports.
The Nova Scotia government's decision to limit Pharmacare coverage of blood glucose test strips for some diabetes patients places a significant financial and health burden on these Nova Scotians and violates the fundamental principle that patients and their healthcare professionals should be able to determine how to manage treatment.
› Verified 1 days ago
| Entity Name | Mydoc Urgent Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689067472 PECOS PAC ID: 3870808322 Enrollment ID: O20150813009853 |
News Archive
A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.
Cancer tissue cells are divided into two major groups: cancer cells and cancer stem cells. CSCs are related to cancer progression and dissemination, so it's necessary to eradicate CSCs in order to cure cancer.
Gilead Sciences Inc. announced Thursday that it plans to partner with Mylan Inc., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. "to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries," the Wall Street Journal reports.
The Nova Scotia government's decision to limit Pharmacare coverage of blood glucose test strips for some diabetes patients places a significant financial and health burden on these Nova Scotians and violates the fundamental principle that patients and their healthcare professionals should be able to determine how to manage treatment.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Noi Walkenstein, DO 2607 Rhawn St, Philadelphia, PA 19152-3038 Ph: (215) 333-0304 | Noi Walkenstein, DO 2607 Rhawn St, Philadelphia, PA 19152-3038 Ph: (215) 333-0304 |
News Archive
A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.
Cancer tissue cells are divided into two major groups: cancer cells and cancer stem cells. CSCs are related to cancer progression and dissemination, so it's necessary to eradicate CSCs in order to cure cancer.
Gilead Sciences Inc. announced Thursday that it plans to partner with Mylan Inc., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. "to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries," the Wall Street Journal reports.
The Nova Scotia government's decision to limit Pharmacare coverage of blood glucose test strips for some diabetes patients places a significant financial and health burden on these Nova Scotians and violates the fundamental principle that patients and their healthcare professionals should be able to determine how to manage treatment.
› Verified 1 days ago
Philippe Olivier Szapary, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 3400 Civic Center Blvd, East Pavilion, 2nd Floor, Philadelphia, PA 19104 Phone: 215-615-4949 | |
Dr. Jamie L. Garfield, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3401 N Broad St, Philadelphia, PA 19140 Phone: 215-707-5864 Fax: 215-707-6867 | |
Maria Esther Escorcia De Leon, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3401 N Broad St, Philadelphia, PA 19140 Phone: 215-707-1622 Fax: 215-707-0943 | |
Cherag Daruwala, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2301 E Allegheny Ave, Suite 190b, Philadelphia, PA 19134 Phone: 215-926-3120 Fax: 215-926-3123 | |
Dr. Robert Burke, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 51 N 39th St, Philadelphia, PA 19104 Phone: 215-662-9436 Fax: 215-243-3208 | |
Eva Hassan Alsheik, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 219 N Broad St, 5th Floor, Philadelphia, PA 19107 Phone: 215-762-6071 | |
Dr. Jason Thomas Ackrivo, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3400 Spruce St, Philadelphia, PA 19104 Phone: 215-614-0871 |